The ABCs of Therapeutic Strategies in Pregnancy and Multiple Sclerosis

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. It will also include a discussion of off-label exposure to medications.

Rising Prevalence of MS and Proportion of Women With MS Who Become Pregnant

3 Different Patients With MS and Family Planning Scenarios

Genetic Risk for MS: Environmental Factors Play a Greater Role

Expert Recommendations for Julie and Mary

Pregnancy-Related Relapse in Multiple Sclerosis: PRIMS Study

Patient Case: Julie

The Dilemma of MS Treatment and Pregnancy

EMA Criteria for Medicinal Product Risk for Fetal Malformations

The Injectables: Interferon and Glatiramer Acetate

Findings From the European Interferon Beta Pregnancy Registry and Population-Based Registries in Finland and Sweden

Oral Therapies: Dimethyl Fumarate Risk in Pregnancy

Oral Teriflunomide: Clinical Study and Post-Marketing Data for Pregnancy Outcomes

Patient Case: Mary

Case Reports of Rebound After Natalizumab and Fingolimod Withdrawal

Use of Corticosteroids to Treat Relapse During Pregnancy

Fingolimod and Pregnancy: Incidence of Malformations and Relapses

Alemtuzumab and Pregnancy: Findings From the German MS and Pregnancy Registry, Plus Cases From Norway and Serbia

Anti-CD20 Monoclonal Antibodies and Pregnancy

B-Cell Depleting Antibodies: B-Cells Should be Checked in Babies of Exposed Mothers

Pregnancy Outcomes After Cladribine Exposure

Pregnancy and Cladribine: EU Label

Mutagenic Cancer Treatments and Risk of Congenital Anomalies in Offspring

Natalizumab and Pregnancy Outcomes

Risk of Natalizumab Exposure or Withdrawal

John's Fatherhood and Potential Risk of MS Medication

Pregnancy and MS: Outcomes and Delivery

Breastfeeding vs Not Breastfeeding: Effect on Relapses

Data for DMT Use During Lactation and Recommendations for Management Strategies in the Postpartum Period

MS and Family Planning: Conclusions

MS and Family Planning: Conclusions (cont)

Abbreviations